Photosensitizing antibody-fluorophore conjugates

Patent metadata

Field	Value
Publication number	US-9358306-B2
Application number	US-201214126060-A
Country	US
Kind code	B2
Filing date	Jun 27, 2012
Priority date	Jul 9, 2010
Publication date	Jun 7, 2016
Grant date	Jun 7, 2016

Abstract

The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm −2 . The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.

First claim

We claim:

1. A method of treating a tumor in a subject, comprising:
administering to the subject a therapeutically effective amount of one or more antibody-IR700 molecules, wherein the antibody specifically binds to a cell surface protein on a tumor cell;
administering one or more therapeutic agents to the subject; and
irradiating the tumor at a wavelength of 660 to 740 nm and at a dose of at least 1 J cm −2 ;
thereby treating the tumor in the subject.

2. The method of claim 1 , wherein the tumor is a cancer.

3. The method of claim 2 , wherein the cancer is a cancer of the breast, liver, colon, ovary, prostate, pancreas, brain, cervix, bone, skin, or lung.

4. The method of claim 1 , wherein the tumor cell is a circulating tumor cell.

5. The method of claim 1 , wherein the cell surface protein is a tumor-specific protein.

6. The method of claim 1 , wherein the cell surface protein is human epidermal growth factor receptor (HER)1, HER2, HER3, HER4, CD5, CD25, CD52, IL-13R, Lewis Y antigen, melanoma-associated antigen (MAGE)1, MAGE2, MAGE3, MAGE4, cancer antigen 125 (CA-125), tumor-associated glycoprotein 72 (TAG-72), gp100, p97 melanoma antigen, human milk fat globule (HMFG), melanoma antigen recognized by T cells 1 (MART1), B melanoma antigen (BAGE) 1, BAGE2, G antigen (GAGE) 1, GAGE2, GAGE3, GAGE4, GAGE5, GAGE6, breast cancer-associated DF3 antigen, New York esophageal squamous cell carcinoma 1 (NY-ESO-1), mesothelin, or carcinoembryonic antigen (CEA).

7. The method of claim 1 , wherein the antibody is cetuximab, panitumumab, zalutumumab, nimotuzumab, matuzumab, trastuzumab, pertuzumab, rituximab, daclizumab, J591 or is an antigen binding fragment thereof.

8. The method of claim 1 , wherein the tumor is irradiated at a wavelength of 680 nm.

9. The method of claim 1 , wherein the one or more antibody-IR700 molecules comprises at least two different antibody-IR700 molecules, wherein a first antibody-IR700 molecule is specific for a first antigen, and a second antibody-IR700 molecule is specific for a different epitope of the first antigen or is specific for a second antigen.

10. The method of claim 1 , wherein the tumor cell is a circulating tumor cell, and wherein irradiating the tumor comprises irradiating the blood by using a device worn by the subject, wherein the device comprises a near infrared (NIR) light emitting diode (LED).

11. The method of claim 1 , wherein the method further comprises:
selecting a subject with a tumor that expresses a cell surface protein that can specifically bind to the one or more antibody-IR700 molecules.

12. The method of claim 1 , wherein the method reduces the volume or size of the tumor by at least 25% relative to the absence of administration of the one or more antibody-IR700 molecules and irradiation.

13. The method of claim 1 , wherein the method increases survival time of the subject relative to an absence of administration of the one or more antibody-IR700 molecules and irradiation.

14. The method of claim 1 , further comprising:
contacting the tumor with one or more antibody-IR700 molecules in an amount less than the therapeutically effective amount; and
irradiating the tumor at a wavelength of 660 to 740 nm and at a dose of at least 0.001 J cm −2 , thereby permitting detection of the tumor.

15. The method of claim 1 , wherein the one or more therapeutic agents is administered about 0 to 8 hours after irradiating the tumor.

16. The method of claim 1 , wherein the one or more therapeutic agents is administered prior to, during, or following administration of the one or more antibody-IR700 molecules.

17. The method of claim 1 , wherein the one or more therapeutic agents is an anti-cancer or anti-neoplastic agent.

18. The method of claim 1 , wherein the one or more therapeutic agents is selected from among a radiotherapeutic agent, a chemotherapeutic agent, an antibiotic, an alkylating agent, an antioxidant and a kinase inhibitor.

19. The method of claim 1 , wherein the one or more therapeutic agents is selected from among a microtubule binding agent, a DNA intercalator or cross-linker, a DNA synthesis inhibitor, a DNA or RNA transcription inhibitor, an antibody, an enzyme, an enzyme inhibitor and a compound that affects gene regulation.

20. The method of claim 1 , wherein the one or more therapeutic agents is selected from among paclitaxel, docetaxel, vinblastine, vindesine, vinorelbine, epothilone, colchicine, dolastatin 15, nocodazole, podophyllotoxin, rhizoxin, actinomycin D, daunorubicin, cisplatin, carboplatin, oxaliplatin, mitomycin C, bleomycin, chlorambucil, cyclophosphamide, methotrexate, 5-fluro-5′-deoxyuridine, 5-fluorouracil, camptothecin, etoposide, formestane, trichostatin, raloxifene, 5-azacytidine, 5-aza-2′-deoxycytidine, tamoxifen, 4-hydroxytamoxifen, mifepristone, imatinib, gefitnib, erlotinib, adriamycine, apigenin, rapamycine, zebularine, cimetidine, interleukin-2 (IL-2), and an anti-CTLA4 antibody.

21. The method of claim 1 , wherein the one or more antibody-IR700 molecules comprises a cetuximab-IR700 molecule.

22. The method of claim 1 , wherein the tumor is a carcinoma.

23. The method of claim 22 , wherein the tumor is a squamous cell carcinoma or adenocarcinoma.

24. The method of claim 22 , wherein the tumor is a carcinoma of the bladder, pancreas, colon, ovary, lung, breast, stomach, prostate, cervix, esophagus or head and neck.

25. The method of claim 1 , wherein the antibody is an antigen-binding antibody fragment selected from a Fab fragment, Fab′ fragment, F(ab)′2 fragment, single chain Fv (scFv) or a disulfide stabilized Fv (dsFv).

Assignees

• Kobayashi Hisataka
• Choyke Peter
• Bernardo Marcelino
• Us Health

Inventors

• Kobayashi Hisataka
• Choyke Peter
• Bernardo Marcelino

Classifications

• A61N5/062

  Photodynamic therapy, i.e. excitation of an agent · CPC title

• A61K49/0036

  Porphyrins (used in photodynamic therapy A61K41/0071 or A61K41/0076; used as targeting group or modifying agent for targeting a therapeutic compound A61K47/546) · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K16/2863

  against receptors for growth factors, growth regulators · CPC title